Findings

What do systematic reviews say?

551 questions · 579 findings · 72 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 158 · 27.3%GRADE not reported 44 · 7.6%Very low 173 · 29.9%Low 112 · 19.3%Moderate 66 · 11.4%High 26 · 4.5%

Intervention not reported

True positives

The review found no eligible studies for this question.

1 finding from 1 review

Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

False negatives

The review found no eligible studies for this question.

1 finding from 1 review

Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

True negatives

The review found no eligible studies for this question.

1 finding from 1 review

Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Modafinil vs placebo

Fatigue · people with ALS/MND

1 finding from 1 review

Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 32 participants
Very low

Modafinil vs placebo

Adverse events · people with ALS/MND

1 finding from 1 review

Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 32 participants
Very low

Exercise vs usual care

Fatigue · people with ALS/MND

1 finding from 1 review

Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Very low

Exercise vs usual care

Adverse events · people with ALS/MND

1 finding from 1 review

Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Very low

Inspiratory muscle training vs sham

Fatigue · people with ALS/MND

1 finding from 1 review

Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Very low

Inspiratory muscle training vs sham

Adverse events · people with ALS/MND

1 finding from 1 review

Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Very low

Repetitive transcranial magnetic stimulation (rTMS) vs sham

Fatigue · people with ALS/MND

1 finding from 1 review

Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 10 participants
Very low

Repetitive transcranial magnetic stimulation (rTMS) vs sham

Adverse events · people with ALS/MND

1 finding from 1 review

Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 10 participants
Very low

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO

Overall survival: BRCA1 or BRCA2

It is very uncertain whether risk‐reducing salpingo‐oophorectomy (RRSO) changes overall survival: BRCA1 or BRCA2 compared with no RRSO (very low certainty).

1 finding from 1 review

Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
HR 0.32 [0.19, 0.54]
3 studies · 2548 participants
Very low

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO according to BRCA mutation status

HGSC mortality: BRCA1 only

It is very uncertain whether risk‐reducing salpingo‐oophorectomy (RRSO) changes HGSC mortality: BRCA1 only compared with no RRSO according to BRCA mutation status (very low certainty).

1 finding from 1 review

Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
HR 0.1 [0.02, 0.41]
2 studies · 1983 participants
Very low

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO according to BRCA mutation status

HGSC mortality: BRCA2 only

1 finding from 1 review

Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1983 participants
Very low

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO according to BRCA mutation status

Breast cancer mortality: BRCA1 only

It is very uncertain whether risk‐reducing salpingo‐oophorectomy (RRSO) changes breast cancer mortality: BRCA1 only compared with no RRSO according to BRCA mutation status (very low certainty).

1 finding from 1 review

Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
HR 0.45 [0.3, 0.67]
4 studies · 2203 participants
Very low

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO according to BRCA mutation status

Breast cancer mortality: BRCA2 only

It is very uncertain whether risk‐reducing salpingo‐oophorectomy (RRSO) changes breast cancer mortality: BRCA2 only compared with no RRSO according to BRCA mutation status (very low certainty).

1 finding from 1 review

Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
HR 0.88 [0.42, 1.87]
3 studies · 5882 participants
Very low

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO according to BRCA mutation status

Quality of life (ovarian cancer risk perception): BRCA1 only

1 finding from 1 review

Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 98 participants
Very low

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO

Overall survival: RRSO alone vs RRSO and RRM

1 finding from 1 review

Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO

Overall survival: RRSO and RRM vs no RRSO

It is very uncertain whether risk‐reducing salpingo‐oophorectomy (RRSO) changes overall survival: RRSO and RRM vs no RRSO compared with no RRSO (very low certainty).

1 finding from 1 review

Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
HR 0.14 [0.02, 0.98]
1 study · 261 participants
Very low

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO

Breast Cancer‐related Death

2 findings from 1 review

Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported
Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 722 participants
Very low